Duc Ha1, Kevin Stephans2, Humberto Choi3, Katrina Zell4, Xiao-Feng Wang4, Omar A Minai3, Daniel P Raymond5, Gregory Videtic2, Peter J Mazzone3. 1. Medicine Institute, Cleveland Clinic; 9500 Euclid Avenue - NA10, Cleveland, OH 44195, USA. 2. Radiation Oncology, Cleveland Clinic; 9500 Euclid Avenue - T28, Cleveland, OH 44195, USA. 3. Respiratory Institute, Cleveland Clinic; 9500 Euclid Avenue - NA23, Cleveland, OH 44195 USA. 4. Quantitative Health Sciences, Cleveland Clinic; 9500 Euclid Avenue - JJN3-01, Cleveland, OH 44195, USA. 5. Thoracic and Cardiovascular Surgery, Cleveland Clinic; 9500 Euclid Avenue - J4-1, Cleveland, OH 44195, USA.
Abstract
OBJECTIVES: Up to 25% of patients with stage I non-small cell lung cancer (NSCLC) are considered high-risk for surgery, due to severe medical comorbidity and/or poor pulmonary reserve. Many of these patients are treated with stereotactic body radiotherapy (SBRT). Prognosis in this subgroup of patients is difficult to determine. We investigated the association of impaired heart rate recovery (HRR) with survival in patients who received SBRT for treatment of early-stage lung cancer. METHODS: We collected data from consecutive patients who, between October 2009 and December 2012, received SBRT for treatment of lung cancer at the Cleveland Clinic, and had 6-minute walk test (6MWT) followed by HRR evaluation performed within six months of initiation of treatment. Impaired HRR was defined as a ≤ 12 beat decrease within the first minute following the 6MWT. Survival analyses were performed using Kaplan-Meier estimates and Cox proportional hazard ratios. RESULTS: Forty nine patients who received SBRT for treatment of early-stage lung cancer had HRR data available. Thirty two (65%) patients had impaired HRR following the 6MWT. In univariable and multivariable Cox regression analyses, impaired HRR was associated with poorer survival (HR: 11.0, 95% CI: 1.42 - 84.4, p = 0.004, and HR: 15.8, 95% CI: 1.96 - 128.0, p = 0.010, respectively). The 2-year overall survival rates were 52.6% for those with impaired HRR, and 94.1% for those with normal HRR. CONCLUSION: Impaired HRR was associated with poorer survival in patients who received SBRT for treatment of early-stage lung cancer. HRR following the 6MWT can be one of the factors considered in patient selection for treatment with SBRT, along with other medical comorbidities.
OBJECTIVES: Up to 25% of patients with stage I non-small cell lung cancer (NSCLC) are considered high-risk for surgery, due to severe medical comorbidity and/or poor pulmonary reserve. Many of these patients are treated with stereotactic body radiotherapy (SBRT). Prognosis in this subgroup of patients is difficult to determine. We investigated the association of impaired heart rate recovery (HRR) with survival in patients who received SBRT for treatment of early-stage lung cancer. METHODS: We collected data from consecutive patients who, between October 2009 and December 2012, received SBRT for treatment of lung cancer at the Cleveland Clinic, and had 6-minute walk test (6MWT) followed by HRR evaluation performed within six months of initiation of treatment. Impaired HRR was defined as a ≤ 12 beat decrease within the first minute following the 6MWT. Survival analyses were performed using Kaplan-Meier estimates and Cox proportional hazard ratios. RESULTS: Forty nine patients who received SBRT for treatment of early-stage lung cancer had HRR data available. Thirty two (65%) patients had impaired HRR following the 6MWT. In univariable and multivariable Cox regression analyses, impaired HRR was associated with poorer survival (HR: 11.0, 95% CI: 1.42 - 84.4, p = 0.004, and HR: 15.8, 95% CI: 1.96 - 128.0, p = 0.010, respectively). The 2-year overall survival rates were 52.6% for those with impaired HRR, and 94.1% for those with normal HRR. CONCLUSION: Impaired HRR was associated with poorer survival in patients who received SBRT for treatment of early-stage lung cancer. HRR following the 6MWT can be one of the factors considered in patient selection for treatment with SBRT, along with other medical comorbidities.
Entities:
Keywords:
Stereotactic body stereotactic body radiotherapy; early-stage lung cancer; heart rate recovery; prognosis
Authors: Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy Journal: JAMA Date: 2010-03-17 Impact factor: 56.272
Authors: Christopher J Lettieri; Steven D Nathan; Robert F Browning; Scott D Barnett; Shahzad Ahmad; Andrew F Shorr Journal: Respir Med Date: 2006-03-20 Impact factor: 3.415
Authors: Mojgan Taremi; Andrew Hope; Max Dahele; Shannon Pearson; Sharon Fung; Thomas Purdie; Anthony Brade; John Cho; Alexander Sun; Jean-Pierre Bissonnette; Andrea Bezjak Journal: Int J Radiat Oncol Biol Phys Date: 2011-03-04 Impact factor: 7.038
Authors: Rafael Golpe; Luis A Pérez-de-Llano; Lidia Méndez-Marote; Alejandro Veres-Racamonde Journal: Respir Care Date: 2013-01-15 Impact factor: 2.258
Authors: Jeffrey J Swigris; Jeff Swick; Frederick S Wamboldt; David Sprunger; Roland du Bois; Aryeh Fischer; Gregory P Cosgrove; Stephen K Frankel; Evans R Fernandez-Perez; Dolly Kervitsky; Kevin K Brown Journal: Chest Date: 2009-04-24 Impact factor: 9.410